A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

185 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2021-06-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Further studies are needed to establish the optimal diet for treating T2D.

The investigators wishes to investigate whether a low carbohydrate diet, high in monounsaturated fats (LCD) will affect cardiovascular function, metabolism and the liver.

135 participants with T2D, will be following either a LCD, or a regular diabetes diet (RDD) for 6 months. Measurements and investigations will be performed at baseline and after 6 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

POLY-unsaturated Fatty Acids in the Preservation of Dietary Effects on Hepatosteatosis and Energy Metabolism in Type 2 Diabetes

NCT03047668

Type 2 Diabetes NAFLD Obesity +3 more

UNKNOWN NA

Effect of High Monounsaturated Fat Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes

NCT00622960

Overweight Obesity Type 2 Diabetes

COMPLETED PHASE1

Canadian Trial of Dietary Carbohydrates in Diabetes

NCT00223574

Type 2 Diabetes

COMPLETED NA

Prevention of Type 2 Diabetes Mellitus by Changes in Diet

NCT02250066

Prediabetes

COMPLETED NA

Low Glycemic Index Diet (With Canola Oil) for Type 2 Diabetics

NCT01348568

Type 2 Diabetes

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type 2 diabetes (T2D) is an increasing global problem, especially in developing countries. T2D is associated with an increased risk of cardiovascular disease (CVD), where hyperglycemia is especially important for microvascular damage.

Previous studies in T2D on reduced carbohydrate intake has shown beneficial effects on glycemic control, indicated by reduction in HbA1c, fasting insulin and 2h-glucose (OGTT) values. However further studies are needed to establish the optimal diet for treating T2D.

The investigators wishes to investigate whether a low carbohydrate diet, high in monounsaturated fats will:

1. Improve glycemic control, dyslipidemia and metabolic markers in T2D despite unchanged anti-diabetic treatment.
2. Improve endothelial function assessed by flow-mediated vasodilation (FMD) in the brachial artery as well as microvascular damage assessed by retinal scan, urine albuminuria and minimal forearm vascular resistance (MFVR).
3. Improve Non-Alcoholic Fatty Liver Disease (NAFLD) assessed by \>2 points reduction in NAFLD Activity score with at least 1 point reduction in either lobular inflammation or hepatocellular ballooning, without worsening of fibrosis.
4. Improve quality of life
5. Improve gut dysbiosis

The study will be conducted through a 6 month randomized controlled trial with 135 participants with type 2 diabetes. 90 participants will be randomized to the intervention group, following a LCD, and 45 participants will be randomized to the control group (regular diet for diabetes, RDD). The below described measurements will be conducted before baseline and after 6 months, and the participants will fill out a QoL questionnaire at 0, 3 and 6 months.

Planned examinations are ultrasound assessment of flow-mediated vasodilation, Dual-energy X-ray absorptiometry (DEXA-scan), retina scan, liver biopsy, liver-scans, blood, urine, hair, saliva and feces. Accelerometers will be applied before, during and after the study to evaluate compliance in unchanged exercise pattern. Compliance with diet will be evaluated by a clinical dietitian and through food diaries.

Baseline histology from the first 50 participants suggest that the current inclusion criteria doesn't cover the full spectrum of NAFLD (NASH and fibrosis) as expected. Further 50 participants who will have had diabetes for more than 10 years and who will not fulfill inclusion criteria number 1 and 2 will be included. On this group of participants we will only perform liver-investigations and DEXA-scan. This group of participants, will not affect the timeschedule of the main study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type2 Diabetes Nonalcoholic Steatohepatitis Non-Alcoholic Fatty Liver Disease Atherosclerosis Dyslipidemias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control-group

The control group will be eating a regular diabetes diet according to the Danish National Recommendations

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention-group

Intervention-group will be eating a low carbohydrate diet, high in monounsaturated fats

Group Type EXPERIMENTAL

Low carbohydrate diet high in monounsaturated fats

Intervention Type DIETARY_SUPPLEMENT

Participants will have to change their diet during 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low carbohydrate diet high in monounsaturated fats

Participants will have to change their diet during 6 months

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LCD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Duration of established T2D for more than six months and less than five years and HbA1c in compliance with T2D (above 48 mmol/mol), but without need for adjustment of antidiabetic treatment\*
2. Serum cholesterol below 4.5 mmol/l and LDL cholesterol below 2.5 mmol/l at inclusion\*\*
3. Age of 18 or above
4. Stable diabetic treatment three months prior to inclusion\*\*\*
5. Be able to read and understand Danish language
6. Signed written consent

* based on the assumption that metabolic and cardiovascular changes are less likely to be reversible in patients with longstanding T2D. HbA1c and need for adjustment and if the patient is eligible for inclusion will be evaluated individually based on the patients current treatment and current HbA1c by the project responsible. If the patient has duration of diabetes \> 5 years but with current treatment ≤ 2 oral antidiabetic drugs and without insulin treatment, the patient will be accepted for enrolment.

* To avoid changes in lipid-lowering treatment during follow-up total cholesterol should be below 4.5 mmol/l and LDL cholesterol below 2.5 mmol/l at inclusion. Higher levels may be accepted if the patient cannot tolerate lipid-lowering treatment \*\*\*Patients can be enrolled three months after medication change

Exclusion Criteria

1. Low carbohydrate diet prior to inclusion
2. Hypoglycemic unawareness
3. Excessive weight loss within the last three months, defined as more than 10 kilograms
4. Current treatment with glucocorticoids (systemic)
5. Continuous treatment with steatosis-inducing drugs (e.g. carbamazepine)
6. Treatment with antibiotics up to 2 months before inclusion\*
7. Treatment with chemotherapy
8. Pregnancy or expected pregnancy within the next 6 months
9. Active alcohol overuse\*\*
10. Active cancer
11. Significant co morbidity including liver disease
12. Poor compliance \*Participants can be rescheduled to be included 2 months after use of antibiotics \*\* Prior alcohol overuse and eligibility will be evaluated individually

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No